Your search has found 328 articles in the database for the term 'Cognitive Function'
Click
here to filter this large number of results.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease
Salloway, Stephen,
Sperling, Reisa,
Fox, Nick C.,
Blennow, Kaj,
Klunk, William,
Raskind, Murray,
Sabbagh, Marwan,
Honig, Lawrence S.,
Porsteinsson, Anton P.,
Ferris, Steven,
Reichert, Marcel,
Ketter, Nzeera,
Nejadnik, Bijan,
Guenzler, Volkmar,
Miloslavsky, Maja,
Wang, Daniel,
Lu, Yuan,
Lull, Julia,
Tudor, Iulia Cristina,
Liu, Enchi,
Grundman, Michael,
Yuen, Eric,
Black, Ronald,
Brashear, H. Robert
...by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog11, with scores ranging...
A multidimensional home-based care coordination intervention for elders with memory disorders: the maximizing independence at home (MIND) pilot randomized trial
Samus, Quincy M.,
Johnston, Deirdre,
Black, Betty S.,
Hess, Edward,
Lyman, Christopher,
Vavilikolanu, Amrita,
Pollutra, Jane,
Leoutsakos, Jeannie-Marie,
Gitlin, Laura N,
Rabins, Peter V.,
Lyketsos, Constantine G.
...of 303 community-living elders.; Setting: 28 postal code areas of Baltimore, MD.; Participants: Age 70+ years, with a cognitive disorder, community-living, English-speaking, and having a study partner available.; Intervention: 18-month...
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Rosas, H. D.,
Doros, G.,
Gevorkian, S.,
Malarick, K.,
Reuter, M.,
Coutu, J.-P.,
Triggs, T. D.,
Wilkens, P. J.,
Matson, W.,
Salat, D. H.,
Hersch, S. M.
...Objective: To assess the safety and tolerability of high-dose creatine, the feasibility of enrolling premanifest and 50% at-risk subjects in a prevention trial, and the potential of cognitive, imaging,...
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease
Schwam, Elias M.,
Nicholas, Timothy,
Chew, Robert,
Billing, Clare B.,
Davidson, Wendy,
Ambrose, Darlene,
Altstiel, Larry D.
...Concomitant acetylcholinesterase inhibitor or memantine use was excluded. The primary outcome was the Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog). The Neuropsychiatric Inventory (NPI), Clinical Global Impression-Improvement scale (CGI-I)...
Improvements in gait characteristics after intensive resistance and functional training in people with dementia: a randomised controlled trial
Schwenk, Michael,
Zieschang, Tania,
Englert, Stefan,
Grewal, Gurtej,
Najafi, Bijan,
Hauer, Klaus
...and Walk-Ratio (P = 0.554). Interestingly, low baseline motor status, but not cognitive status, predicted positive training response (relative change in gait speed from baseline).; Conclusion: The intensive, dementia-adjusted training...
The ALS-FTD-Q: a new screening tool for behavioral disturbances in ALS
Raaphorst, Joost,
Beeldman, Emma,
Schmand, Ben,
Berkhout, Joris,
Linssen, Wim H. J. P.,
van den Berg, Leonard H.,
Pijnenburg, Yolande A.,
Grupstra, Hepke F.,
Weikamp, Janneke G.,
Schelhaas, H. Jurgen,
Papma, Janne M.,
van Swieten, John C.,
de Visser, Marianne,
de Haan, Rob J.
...ALS-FTD-Q showed construct validity because it correlated highly with other behavioral measures (r = 0.80 and 0.79), moderately with measures of frontal functions and global cognitive functioning (r = 0.37;...
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease
Trzepacz, Paula T.,
Cummings, Jeffrey,
Konechnik, Thomas,
Forrester, Tammy D.,
Chang, Curtis,
Dennehy, Ellen B.,
Willis, Brian A.,
Shuler, Catherine,
Tabas, Linda B.,
Lyketsos, Constantine
...Neuropsychiatric Inventory. Secondary measures included the Cohen-Mansfield Agitation Inventory, Cornell Scale for Depression in Dementia, Frontal Systems Behavior Inventory (FrSBe), and Alzheimer’s Disease Assessment Scale-Cognitive. Efficacy was analyzed using mixed-effects...